Skip to content
Graham Pockley

Graham Pockley

Professor of Immunobiology

School of Science & Technology

Staff Group(s)


Professor of Immunobiology, John van Geest Cancer Research Centre & Centre for Health, Ageing and Understanding Disease (CHAUD)

Graham Pockley is Professor of Immunobiology and the former Director of the John van Geest Cancer Research Centre. Research in the Centre focuses on the discovery and application of new cancer biomarkers for detecting cancer, monitoring disease progression and developing new immunotherapeutic approaches. Progress in these areas is based on a fundamental understanding of cancer cell biology and immunobiology. He is also a member of the Centre for Health, Ageing and Understanding Disease (CHAUD) at Nottingham Trent University and a member of the Cancer Biology, Immunology and Therapeutics Theme.

The John van Geest Cancer Research Centre incorporates state-of-the-art technologies for discovering the genetic basis of the disease and developing new methods of diagnosis and treatment and is therefore well equipped for the challenge of modern day cancer research.

Career overview

Having obtained a Doctor of Philosophy for studies investigating the immunomodulatory properties of human placental protein 14 from Sheffield City Polytechnic (now Sheffield Hallam University) in 1988, Professor Pockley undertook a 2-year postdoctoral fellowship studying ocular mucosal immunoregulation in the Department of Immunology and Microbiology at Wayne State University, Detroit, USA. In January 1990, he returned to the UK to take up a Lectureship and direct the experimental transplantation programme in the Professorial Surgical Unit at the Medical College of St. Bartholomew´s Hospital, London. He returned to Sheffield as a Lecturer at the University of Sheffield Medical School in September 1994, where he was promoted to Reader in Immunobiology in 1996 and Professor of Immunobiology in 2004.

Professor Pockley was the recipient of a Yorkshire Enterprise Fellowship (2009-2010), the aim of which was to deliver training in Entrepreneurship and Commercial Exploitation. The Fellowship complemented his previous experience with the commercial sector via research contracts with Biotechnology companies in Canada and was primarily focussed on the development of a global resource for flow cytometry and related techniques ( Chromocyte Limited was incorporated in the UK and launched in July 2010. Since 2015, Professor Pockley has also been the CEO of multimmune GmbH (, a clinical stage biopharmaceutical company based in Munich, Germany which is delivering innovative therapeutics and diagnostics ('theranostics') for treating and managing a range of cancer types, especially therapy-resistant disease. Professor Pockley's experience in these and associated areas positions him well for the provision of academic and commercial insight in areas relating to immunobiology, flow cytometry, cell analysis and cancer theranostics.

Professor Pockley became the Associate Director of the John van Geest Cancer Research Centre at Nottingham Trent University in May 2012 and its Director in September 2016. He stepped down from this this role in September 2020, but retains a Professorship at Nottingham Trent University. He has also held an Honorary Professorship in the Department of Oncology and Metabolism at The University of Sheffield (2012 - 2021).

Research areas

Graham Pockley is Emeritus Professor of Immunobiology and the former Director of the John van Geest Cancer Research Centre. Research in the Centre is delivered as part of the Centre for Health, Ageing and Understanding Disease (CHAUD) and the Cancer Biology, Immunology and Therapeutics Theme.

Professor Pockley's interests focus on the immunobiology of heat shock (stress) proteins and better understanding immunoregulatory mechanisms and their impact on disease processes. Professor Pockley’s current interests relate to tumour-mediated immunoregulation and its influence on the induction of protective anti-tumour immunity, the influence of tumours on the phenotype and function of innate immune responses, immune profiling and the identification of immunological biomarkers of disease presence, severity, progression and treatment sensitivity, as well as the development of new cancer diagnostics and immunotherapeutics.

Professor Pockley's work primarily involves cell analysis using multi-parameter flow cytometry, complementary analytical techniques, natural killer (NK) cell-based immunotherapeutics and the commercialisation of technology and know-how. Professor Pockley led the immune reconstitution (mechanistic) element of a National Institute for Health Research (NIHR) funded multicentre Phase II clinical trial evaluating the therapeutic potential of autologous stem cell transplantation for patients with treatment refractory Crohn’s Disease (ASTIClite). He was also Co-Investigator on an NIHR funded project developing a new diagnostic approach for predicting response to chemotherapy in patients with breast cancer. Professor Pockley is an inventor on a granted patent (PAP-based vaccine for prostate cancer).

Professor Pockley has supervised students in a range of subject areas relating to immunoregulatory mechanisms in disease processes, but is no longer accepting Doctoral Candidates. However, information on research degree opportunities may be obtained on the NTU Research Degrees website

In 2020, PLOS Biology1 identified Professor Pockley as being in the top 0.5% (in terms of career-long citation impact and citation impact during the calendar year 2019) of the ~6.9 million scientists that have published at least 5 papers since 1995 across all disciplines. Professor Pockley remained in the top 0.5% of scientists in an 'Updated science-wide author databases of standardized citation indicators' which was published in August 2021 and includes citations up to the year 2020.

1PLOS Biology |

External activity

Sponsors and collaborators

Professor Pockley has secured and managed a portfolio of internationally innovative research totalling ~ £7 million, including projects funded by national charity, charitable trust, governmental (UK, Germany, USA) and commercial sources such as the NIHR, UK Research & Innovation, US and Canadian biopharmaceutical companies, the Deutsche Forschungsgemeinschaft, Germany, the National Institutes of Health, USA, the Food Standards Agency and the Welcome Trust, of which £3,731,000 (£1,050,000 to NTU) is currently active.

Professor Pockley collaborates with a number of international groups, and has a long-standing collaborative relationship with Professor Gabriele Multhoff in the Center for Translational Cancer Research (TranslaTUM) at the University Hospital Klinikum rechts der Isar, Technische Universität München, one of Germany's premier Universities. These studies are focussed on the development of novel immunotherapeutic approaches for targetting membrane Hsp70 positive tumours.

Ongoing and Recent Projects

  • A single-dose DNA vaccine platform to safely induce protective immunity against Zika virus: Innovate UK (on behalf of the UK Vaccine Network; April 2022 - April 2023; led by the University of Nottingham (NTU subcontractor);
  • A novel DNA vaccine that delivers long lasting immunity by stimulating high avidity CD8 T cells and strong neutralising antibodies: Innovate UK; September 2020 - March 2022; led by Scancell Limited and in collaboration with the University of Nottingham;
  • Correlating the cellular content of umbilical cord blood transplants with clinical outcomes. Anthony Nolan Trust; January 2020 - December 2020;
  • Development of new immune-based treatments for Glioblastoma Multiforme (GBM): The Headcase Cancer Trust; October 2019 - October 2021;
  • National Institute for Health Research (NIHR) i4i Reference Number II-LA-0417-20004: Developing a diagnostic tool, using SPAG5, for predicting clinical benefit from standard anthracycline combination (AC) chemotherapy in breast cancer: National Institute of Health Research (NIHR) i4i Programme:  June 2018 – December 2021;
  • National Institute for Health Research (NIHR) EME Project: 15/178/09 - Autologous Stem cell Transplantation In refractory Crohn’s disease - Low Intensity Therapy Evaluation (ASTIClite): National Institute of Health Research (NIHR) EME Programme; March 2018 – December 2021;
  • Implementation of a novel immune gene profiling platform for the generation and analysis of high-dimensional transcriptomic data from human tumours (Co-funded PhD Studentship): NanoString Technologies, Seattle, USA: October 2017 – September 2020;
  • Micro-environmental targets for restoring anti-tumor immunity in childhood acute leukemia: Qatar National Research Fund: September 2016 – March 2020;
  • Genomic, proteomic, functional and therapeutic profiling of primed natural killer (NK) cell populations: INmune Bio International Ltd., UK; May 2016 - July 2018;
  • Towards the development of new immunotherapies for leukaemia and other cancers: The Roger Counter Foundation: March 2016 – March 2019;
  • Towards the development of a new immunotherapy for the treatment of Glioblastoma multiforme: The Headcase Cancer Trust; October 2015 - October 2018.



Professor Pockley currently has > 220 publications. Professor Pockley has also co-edited a Special Issue entitled ‘Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective’ (Edkins A.L., Price J.T., Pockley A.G., Blatch G.L. eds) for Philosophical Transactions of the Royal Society B, and books entitled ‘Molecular Chaperones and Cell Signalling’ (Henderson B., Pockley A.G. eds - Cambridge University Press),‘Prokaryotic and Eukaryotic Stress Proteins in Infectious Disease’ (Pockley A.G., Santoro M.S., Calderwood S.K. eds - Springer, New York) and ‘Cellular Trafficking of Molecular Chaperones in Health and Disease’ (Henderson B., Pockley A.G. eds - Springer, New York).

Selected Publications (2017 - present)

Le Vu P., Vadakekolathu J., Idri S., Nicholls H., Cavaignac M., Reeder S., Khan M., Christensen D., Pockley A.G., McArdle S.E. (2022) A mutated Prostatic Acid Phosphatase (PAP)-peptide based vaccine induces PAP-specific CD8+ T cells with ex vivo cytotoxic capacities in HHDII/DR1 transgenic mice. Cancers, in press.

Howard F., El-Janabi H., Staniland S., Kennerley A., Patel P., Cox K., Allwood D., Smith E., Vadakekolathu J., Pockley A.G., Connor J., Collado-Rojas C., Muthana M. (2022) Bugs as drugs – Bacterial derived nanomagnets enhance tumour targeting and oncolytic activity of HSV-1 virus. Small 2022, e2104763. doi: 10.1002/smll.202104763

Cosma G., McArdle S.E.B., Foulds G.A., Hood S.P., Reeder S., Johnson C., Khan M.A., Pockley A.G. (2021) Prostate Cancer: Early detection and assessing clinical risk using Deep Machine Learning of high dimensional peripheral blood flow cytometric phenotyping data. Frontiers in Immunology, 16 December 2021. doi: 10.3389/fimmu.2021.786828.

Cossarizza A., Chang H-D., Radbruch A., et al.  (2021) Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European Journal of Immunology, 51: 2708–3145.

Bashiri Dezfouli A., Yazdi M., Pockley A.G., Khosravi M., Kobold S., Wagner E., Multhoff G. (2021) NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development. Cells, 10 (12). doi 10.3390/cells10123390:

McArdle S.E.M., Pawelec G., Pockley A.G., Johansen P. (2021) Editorial: Frontiers’ Research Topic ‘Cancer Vaccines: Time to Think Differently!’ Frontiers in Immunology, 12:771319. doi: 10.3389/fimmu.2021.771319

Tulotta C., Lefley D.V., Moore C.K., Amariutei A.E., Spicer-Hadlington A.R., Quayle L.A., Hughes R.O., Ahmed K., Cookson V., Evans C.A., Vadakekolathu J., Heath P., Francis S., Pinteaux E., Pockley A.G., Ottewell P.D. (2021) IL-1B drives opposing innate immune responses in primary tumours and bone metastases, limiting treatment options in breast cancer. npj Breast Cancer, 7:95. doi: 10.1038/s41523-021-00305-w

Brentville V.A., Vankemmelbeke M., Methingham R.L., Symonds P., Cook K.W., Urbanowicz R.A., Tsoleridis T., Coleman C.M., Chang K-C., Skinner A., Dubinina E., Daniels I., Shah S., Dixon J.E., Pockley A.G., Adams S.E., Paston S.J., Daly J.M., Ball J.K., Durrant L.G. (2021). A novel bivalent DNA vaccine encoding both spike protein receptor-binding domain and nucleocapsid protein of SARS-CoV-2 to elicit T cell and neutralising antibody responses that cross react with variants. bioRxiv, doi: 10.1101/2021.06.18.448932.

Almshayakhchi R., Nagarajan D., Vadakekolathu J., Reeder S., Brentville V., Metheringham R., Durrant L., Pockley A.G., McArdle S.E.B. (2021) A novel HAGE/WT1-ImmunoBody™ vaccine combination enhances anti-tumour responses when compared to either vaccine alone. Frontiers in Oncology,doi: 10.3389/fonc.2021.636977.

Nagarajan D., Pearson J., Brentville V., Metheringham R., Ahmad M., Durrant L., Pockley A.G., McArdle S.E.B. (2021) Helicase antigen (HAGE)-derived vaccines induce immunity to HAGE and ImmunoBody™-HAGE DNA vaccine delays the growth and metastasis of HAGE-expressing tumors in vivo. Immunology & Cell Biology, Jun 9.  doi: 10.1111/imcb.12485

Shackleton E.G., Ali H.Y., Khan M., Pockley A.G., McArdle S.E. (2021) Novel combinatorial approaches to tackle the immunosuppressive microenvironment of prostate cancer. Cancers, 13(5), 1145; doi: 10.3390/cancers13051145

Cuzzubbo S., Mangsbo S., Habra K., Nagarajan D., Pockley A.G., McArdle S.E.B. (2021) Cancer vaccines: Adjuvant potency, importance of age, lifestyle and treatments. Frontiers in Immunology, 17 Feb 2021. doi:

Kwan A., Winder N., Atkinson E., Al-Janabi H., Allen R.J.,  Hughes R., Moamin M., Louie R., Evans D., Hutchinson M., Capper D., Cox K., Handley J., Wilshaw A., Kim T., Tazzyman S.J., Srivastava S., Ottewell P., Vadakekolathu J., Pockley A.G., Lewis C.E., Brown J.E., Danson S.J., Conner J., Muthana M. (2020) Macrophages mediate the anti-tumor effects of the oncolytic virus HSV1716 in mammary tumors. Molecular Cancer Therapeutics, 20 (3): 589-601 doi: 10.1158/1535-7163.MCT-20-0748.

Pearson J.R.D., Cuzzubbo S., McArthur S., Durrant L., Adhikaree J., Tinsley C.J., Pockley A.G., McArdle S.E.M. (2020) Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Frontiers in Immunology, 11:582106. doi: 10.3389/fimmu.2020.582106/full.

Multhoff G., Seier S., Stangl S., Sievert W., Shevtsov M., Werner C., Pockley A.G., Blankenstein C., Hildebrandt M., Offner R., Ahrens N., Kokowski K., Hautmann M., Rödel C., Fietkau R., Lubgan D., Huber R., Hautmann H., Duell T.,  Molls M., Specht H., Haller B., Devecka M., Sauter A., Combs S. (2020) Targeted natural killer cell based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy – a randomized phase II clinical study. Clinical Cancer Research, 26:5368-5379. doi: 10.1158/1078-0432.CCR-20-1141.

Hood S.P., Cosma G., Foulds G.A., Johnson C., Reeder S., McArdle S.E., Khan M.A., Pockley A.G. (2020). Identifying prostate cancer and its clinical risk in asymptomatic men using Machine Learning of high dimensional peripheral blood flow cytometric natural killer cell subset phenotyping data. eLife, e50936 doi: 10.7554/eLife.50936.

Abdel-Fatah T.M.A., Ball G.R., Thangavelu P.U., Reid L.E., McCart Reed A.E., Saunus J.M., Duijf P.H.G., Simpson P.T., Lakhani S.R., Pongor L., Győrffy B., Moseley P.M., Green A.R., Pockley A.G., Caldas C., Ellis I.O., Chan S.Y.T. (2020) Sperm associated antigen 5 (SPAG5) predicts and monitors response to endocrine and chemo-therapies in oestrogen receptor positive (ER+) breast cancer (BC): A potential tool for BC precision medicine. JAMA Network Open, 3(7):e209486, doi: 10.1001/jamanetworkopen.2020.9486.

Vadakekolathu J., Minden M.D., Hood T., Church S.E., Reeder S., Altmann H., Sullivan A.H., Viboch E.J., Patel T., Ibrahimova N., Warren S.E., Arruda A., Liang Y., Smith T.H., Foulds G.A., Bailey M.D., Gowen-MacDonald J., Muth J., Schmitz M., Cesano A., Pockley A.G., Valk P.J.M., Lowenberg B., Bornhauser M., Tasian S.K., Rettig M.P., Davidson-Moncada J., DiPersio J.F., Rutella S. (2020) Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Science Translational Medicine, 12: eaaz0463.

Gruet M., Cotton D., Coveney C., Boocock D.J., Wagner S., Komorowski L., Rees R.C., Pockley A.G., Garner A.C., Wallis J.D., Miles A.K., Powe D.G (2020). β2-adrenergic signalling promotes cell migration by upregulating expression of the metastasis-associated molecule LYPD3. Biology, 9(2), 39; doi: 0.3390/biology9020039.

Gaipl U.S., Multhoff G., Pockley A.G., Rödel F (2020) Editorial: Radioimmunotherapy – Translational Opportunities and Challenges. Frontiers in Oncology,  10:190. doi: 10.3389/fonc.2020.00190.

Nicklin M., Hickman G.J, Pockley A.G., Perry C.C. (2020) Materials-based approach for interrogating human prostate cancer cell adhesion and migratory potential using a Fluoroalkylsilica culture surface. ACS Applied Bio Materials, 3:495-504. doi: 10.1021/acsabm.9b00940

Pockley A.G, Vaupel P., Multhoff G (2020) NK cell-based therapeutics for lung cancer. Expert Opinion on Biological Therapy, 20(1):23-33. doi: 10.1080/14712598.2020.1688298.

Cossarizza A., Chang H-D., Radbruch A. et al  (2019) Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 49: 1457-1973. doi: 10.1002/eji.201970107.

Sabry M., Zubiak A., Hood S.P., Arellano-Ballestro H., Simmonds P., Cournoyer E., Mashar M., Pockley A.G., Lowdell M.W. (2019) Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures. PLoS ONE, 14(6): e0218674, doi: 10.1371/journal.pone.0218674.

Snowden J.A., Hawkey C., Swaby L., Mellor K., Emsley R., Mandefield L., Lee E., Badoglio M., Polge E., Labopin M., Gribben J., Pockley A.G., Foulds G.A., Lobo S., Parkes M., Satsangi J., Papaioannou D., Lindsay J.O., on behalf of the Autologous Stem Cell Transplantation in Refractory CD Low Intensity Therapy Evaluation Study Investigators and the European Society for Blood and Bone Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) (2019). Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study. BMC Gastroenterology 19:82, doi: 10.1186/s12876-019-0992-2.

Dring K.J., Cooper S.B., Morris J.G., Sunderland C., Foulds G.A., Pockley A.G., Nevill M.E. (2019) Multi-stage Fitness Test Performance, V̇O2 peak & adiposity: effect on risk factors for cardio-metabolic disease in adolescents. Frontiers in Physiology, 10:629, doi: 10.3389/fphys.2019.00629.

Wagner S., Vadakekolathu J., Tasian S., Altmann H., Bornhäuser M., Pockley A.G., Ball G.R., Rutella S. (2019) A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multi-cohort study. Blood Advances, 3: 1330-46, doi: 10.1182/bloodadvances.2018030726.

Hood S.P., Foulds G.A., Imrie H., Reeder S., McArdle S.E., Khan M.K. Pockley A.G. (2019) Phenotype and function of activated natural killer cells from patients with prostate cancer: Patient-dependent responses to priming and IL-2 activation. Frontiers in Immunology, 9:3169, doi: 10.3389/fimmu.2018.03169.

Breuninger S., Stangl S., Werner C., Sievert W., Lobinger D., Foulds G.A., Wagner S., Pickhard A., Piontek G., Kokowski K., Pockley A.G., Multhoff G. (2018) Membrane Hsp70 - a novel target for the isolation of circulating tumor cells after epithelial-to-mesenchymal transition. Frontiers in Oncology, 8:497, doi: 10.3389/fonc.2018.00497.

Foulds G.A., Vadakekolathu J., Abdel-Fatah T.M.A. Nagarajan D., Reeder S., Johnson C., Hood S., Moseley P.M., Chan S.Y.T., Pockley A.G., Rutella S., McArdle S.E.M. (2018) Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: Identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Frontiers in Immunology 9:2028, doi: 10.3389/fimmu.2018.02028.

Pockley A.G., Lindsay J.O., Foulds G.A., Rutella S., Gribben J.G., Alexander T., Snowden J.A. on behalf of the EBMT Autoimmune Diseases Working Party (ADWP) and the ASTIClite Study Investigators (2018) Immune reconstitution after autologous Haematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A review on behalf of the EBMT Autoimmune Diseases Working Party and the ASTIClite Study Investigators. Frontiers in Immunology, 9:646. doi: 10.3389/fimmu.2018.00646.

Vadakekolathu J., Johnson C., Schneider A., Buczek M.E., Al-Juboori S., Pockley A.G., Ball G.R., Powe D.G., Regad T. (2018) MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer. Cell Death and Disease, 9(3):344. doi: 10.1038/s41419-018-0364-9.

Pockley A.G., Henderson B (2018) Extracellular cell stress (heat shock) proteins - immune responses and disease: An overview. Philosophical Transactions of the Royal Society B, 373(1738). pii: 20160522. doi: 10.1098/rstb.2016.0522.

Stangl S., Foulds G.A., Fellinger H., Pilkington G.J., Pockley A.G., Multhoff G. (2018) Immunohistochemical and flow cytometric analysis of intracellular and membrane-bound Hsp70, as a putative biomarker of glioblastoma multiforme, using the cmHsp70.1 monoclonal antibody. Methods in Molecular Biology, 1709:307-320. doi: 10.1007/978-1-4939-7477-1_22.

Edkins A.L., Price J.T., Pockley A.G., Blatch GL (2018) Heat shock proteins as modulators and therapeutic targets of chronic disease: an integrated perspective. Philosophical Transactions of the Royal Society B, 373(1738). pii: 20160521. doi: 10.1098/rstb.2016.0521.

Abdel-Fatah T.M.A., Rees R.C., Pockley A.G., Moseley P., Green A.R., Ball G.R., Chan S.Y.T., Ellis I.O., Miles A.K. (2017) The localisation of pre‑mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of Trastuzumab in patients with breast cancer overexpressing HER2. Oncotarget, 8:112245-112257.

Cosma G., McArdle S.E., Reeder S., Foulds G., Hood S., Khan M., Pockley A.G. (2017) Identifying the presence of prostate cancer in individuals with PSA levels <20 ng/ml using computational data extraction analysis of high dimensional peripheral blood flow cytometric phenotyping data. Frontiers in Immunology, 8:1771. doi: 10.3389/fimmu.2017.01771.

Cossarizza A., Chang H-D., Radbruch A., et al (2017). Guidelines for the use of flow cytometry and cell sorting in immunological studies. European Journal of Immunology, 47: 1584-1797.

Dunning-Foreman N., Vadakekolathu J., Laversin S.A., Morgan M.G., Reeder S., Pockley A.G., Rees R.C., Boocock D.J. (2017) A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics. Scientific Reports, 7:40633 | DOI: 10.1038/srep40633.

Selected Additional Key Publications

Abdel-Fatah T.M.A., Agarwal D., Liu D.-X., Russell R., Rueda O.M., Liu K., Moseley P.M., Green A.R., Pockley A.G., Rees R.C., Caldas C., Ellis I.O., Ball G.R., Chan S.Y. (2016) SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. Lancet Oncology, 17: 1004–8.

Cosma G., Acampora G., Brown D., Rees R.C., Khan M., Pockley A.G. (2016) Prediction of pathological stage in patients with prostate cancer: A Neuro-Fuzzy Model. PLoS ONE, 11(6): e0155856. doi:10.1371/journal.pone.0155856.

Abdel-Fatah T.M.A., McArdle S.E., Agarwal D., Moseley P.M., Green A.R., Ball G.R., Pockley A.G., Ellis I.O., Rees R.C., Chan S.Y.T. (2016) HAGE in Triple-Negative Breast Cancer is a novel prognostic, predictive, and actionable biomarker: A transcriptomic and protein expression analysis. Clinical Cancer Research, 22: 905-14.

Saif J.M.S., Vadakekolathu J., Rane S.S., McDonald D., Ahmad A., Mathieu M., Pockley A.G., Durrant L., Metheringham R., Rees R.C., McArdle S. (2014) A novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice. European Journal of Immunology, 44: 994-1004.

Gehrmann M., Stangl S., Foulds G.A., Oelinger R., Breuninger S., Rad R., Pockley A.G., Multhoff G. (2014) Tumor imaging and targeting potential of an Hsp70-derived 14-mer peptide. PLoS ONE 9(8): e105344. doi:10.1371/journal.pone.0105344.

Gehrmann M., Stangl S., Kirschner A., Foulds G.A., Sievert W., Doß B.T., Walch A., Pockley A.G., Multhoff G. (2012) Immunotherapeutic targeting of membrane Hsp70-expressing tumors using recombinant human granzyme B. PLoS ONE 7(7): e41341. doi:10.1371/journal.pone.0041341.

Stangl S., Gehrmann M., Riegger J., Kuhs K., Riederer I., Sievert W., Hube K., Mocikat R., Dressel R., Kremmer E., Pockley A.G., Friedrich L., Vigh L., Skerra A., Multhoff G. (2011) Targeting membrane heat shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proceedings of the National Academy of Sciences USA, 108:733-8.

See a full list of Professor Pockleys publications on ORCID or those that are listed on iREP.

See all of A. Graham Pockley's publications...

Press expertise

  • Breast, Prostate and Brain Cancers
  • Cancer Immunology and Therapeutics
  • Cancer Diagnosis and Prognosis
  • Cancer Immunotherapies
  • Immune-Based Cancer Biomarker Discovery
  • Immune Profiling and Diagnostics
  • Precision and Predictive Medicine
  • Translational Research and Commercialisation
  • Flow Cytometry